



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number:

0 464 727 A2

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 91110799.3

⑮ Int. Cl.⁵: A61K 9/06

⑯ Date of filing: 28.06.91

⑰ Priority: 29.06.90 JP 172914/90

⑲ Date of publication of application:
08.01.92 Bulletin 92/02

⑳ Designated Contracting States:
BE CH DE DK FR GB IT LI LU NL SE

⑷ Applicant: SANTEN PHARMACEUTICAL CO., LTD.
9-19, Shimoshinjo 3-chome
Higashiyodogawa-ku Osaka-shi Osaka
533(JP)

⑵ Inventor: Nishi, Okihiro
6-23-10, Hoshida
Katano-shi, Osaka(JP)
Inventor: Nishi, Kayo
6-23-10, Hoshida
Katano-shi, Osaka(JP)

⑷ Representative: BÜHLING, Gerhard, Dipl.-Chem.
Patentanwaltsbüro Tiedtke-BÜHLING-KINNE
Grupe-Pellmann-Grams Bavariaring 4
W-8000 München 2(DE)

⑶ Composition for debridement of retained lens materials.

⑷ A composition for debridement of retained lens materials is disclosed. The composition comprises a viscoelastic material and ethylenediaminetetraacetic acid or salts thereof dissolved in a physiologically acceptable solution.

Preferably the viscoelastic material is sodium hyaluronate.

EP 0 464 727 A2

FIELD OF THE INVENTION

The present invention relates to a novel composition which is useful for debridement of retained lens materials such as lens epithelial cells by an aspiration during a cataract surgery.

5

DESCRIPTION OF THE PRIOR ART

Cataract, frequently in aged people, is an intractable eye disease and various studies on a treatment of cataract have been made. But at present, the treatment of cataract is finally attained by surgical operations.

10 Cataract surgery has been applied for a long time and various operative methods have been examined. In such operative methods, there are problems how to easily and completely extract an opaque lens, how to prevent postoperative complications, and how to fast and satisfactorily recover from operative damages.

Recently a phacoemulsification procedure is getting widely used to extract the opaque lens. The procedure consists of applying supersonic waves to the cataract in a lens capsule to emulsify it and removing it by aspiration. The procedure has merits that complications caused by a large incision are few and the recovery from operation damages is fast because the incised wound is small.

Formerly, after cataract extraction, the visual acuity of the patient was improved by applying glasses or contact lens, but recently it is widely applied to recover the visual acuity by implanting an intraocular lens.

20 The phacoemulsification procedure is very useful to extract an opaque lens, however, it needs high techniques to remove the retained lens materials such as lens epithelial cells without damaging intraocular tissues.

25 Lens epithelial cells have self-proliferating abilities. If the cells remain after an operation, they cause postoperative complications such as secondary cataract, residual capsular opacification, intraocular lens dislocation, fibrin reaction and phacoanaphylactic endophthalmitis. They can be prevented by thorough removal of the lens epithelial cells.

30 The methods for lens epithelial cell removal can be classified in mechanical means and pharmaceutical means. As a pharmaceutical method, use of ethylenediaminetetraacetic acid (EDTA) is reported as successful. (Brit. J. Ophthalmol., 72 406-408 (1988)). EDTA is used for separating cells in tissue culture. It loosens junctional complex of cells. However, influences of EDTA on intraocular tissues have to be considered.

35 First, it is an influence on corneal endothelial cells. If intercellular junctions are damaged, the functions of corneal epithelial cells can be decompensated, resulting in corneal edema, opaque, etc. If zonules are damaged and partially dissolved by EDTA, a posterior chamber intraocular lens may dislocate or luxate. If zonules are dissolved completely, an implantation of an intraocular lens becomes impossible because a sustaining tissue, namely a lens capsule, disappears. Even if an intraocular lens can be implanted, there exists a high risk to dislocate after an operation. Therefore, it needs to study how to keep EDTA in the lens capsule, namely, how to prevent the leakage of EDTA from the capsular opening incised to remove the cataracts.

40 We found that leakage of EDTA from the opening of the lens capsule can be prevented effectively, when EDTA is mixed with a viscoelastic material with high molecular weight and viscosity, and the mixture is injected into the lens capsule after removal of cataractous lens by endocapsular phacoemulsification procedure with a small anterior capsulotomy

SUMMARY OF THE INVENTION

45

The object of the present invention is to provide a method of treating cataract for debridement of retained lens epithelial cells without leakage of EDTA or salts thereof from anterior capsular opening that is needed for removing cataract.

50 The other object of this invention is to provide a pharmaceutical composition which is used in above mentioned treating method.

55 The inventors, having strenuously studied to achieve the above-mentioned object, have found the fact that when EDTA or salts thereof and viscoelastic material both dissolved in a physiologically acceptable solution are injected into the capsular bag after cataract extraction by endocapsular phacoemulsification-aspiration following the small anterior capsulotomy, EDTA or salts thereof can be effectively prevented from leaking out the capsular bag through the incised opening. EDTA or salts thereof does not leak out of the capsular bag so much to influence the intraocular tissues, and the lens epithelial cells which are difficult to sufficiently be removed even with the phacoemulsification-aspiration can be removed even with a low level of aspiration power.

Retained lens materials are various substances remaining in the lens capsule during a cataract surgery, and the representative example of them is lens epithelial cells.

According to the present invention we provide a composition for debridement of retained lens materials, especially lens epithelial cells, comprising a viscoelastic material and EDTA or salts thereof both dissolved in a physiologically acceptable solution.

Preferably the viscoelastic material is sodium hyaluronate.

DESCRIPTION OF THE PREFERRED EMBODIMENT

10 Preferable salts of EDTA in this invention are disodium salt, trisodium salt and tetrasodium salt, and a more preferable salt is disodium salt.

The concentration of EDTA or salts thereof in the solution can be defined according to the binding strength of lens epithelial cells differing from patient to patient. The preferable concentration is 5 to 50 millimol/l, (hereinafter referred to as mM).

15 As the viscoelastic material, clinically applied high molecular materials can be used. Preferable examples of such materials are hyaluronic acid or salts thereof, methylcellulose, hydroxymethylcellulose, carboxyvinyl polymer, polyvinylpyrrolidone, polyvinylalcohol, polyacrylamide, kitin and collagen. In view of a protection of eye tissues, sodium hyaluronate is more preferable.

The above mentioned viscoelastic material is used in the form of physiologically acceptable solutions.

20 The concentration of the viscoelastic material in the solutions is selected according to the desired viscosity, and usually 0.1 to 5% by weight, preferably 0.5 to 3.0% by weight. As the solution of the viscoelastic material, aqueous solution of sodium hyaluronate is widely used in ophthalmologic surgeries, and is preferable because of its protection effects on eye tissues. The molecular weight of sodium hyaluronate is not limited but selected according to the desired viscosity, and is in the range of about 600,000 to 25 4,000,000, preferably 800,000 to 3,000,000. The viscosity of sodium hyaluronate solution depends on its concentration and molecular weights, and is 2,000 to 200,000 cP, preferably 10,000 to 100,000 cP.

The pH value of the preparations according to the present invention may be that ophthalmologically applied, and preferably in the range of 4 to 8.

30 No special technology is required for making the preparations of this invention. For example, EDTA or salts thereof and the viscoelastic material such as sodium hyaluronate are dissolved in a physiologically acceptable solution to make the preparations, and if necessary pharmaceutically acceptable excipients, buffers, pH adjusting agent etc. can be added. Examples of the physiologically acceptable solution are isotonic sodium chloride solution, distilled water for injection adjusted to physiological condition by adding isotonic agents such as sodium chloride and potassium chloride, and balanced salt solution (BSS).

35 A typical method of clinically applying the pharmaceutical composition according to the present invention will be briefly described in the following.

40 After the anterior lens capsule of a cataract patient is incised to form a small opening, and the cataractous lens materials are removed with phacoemulsification-aspiration procedure, the preparation of this invention is injected through the capsular opening. Two minutes after the injection, the retained lens materials including lens epithelial cells are removed together with the preparation while the interior of the capsule being irrigated with an irrigation solution. The amount of the injected preparation can be selected according to the volume of the patient's lens capsule (about 0.2 ml).

This invention affords the following effects or advantages.

45 On a cataract surgery, lens epithelial cells can be easily removed by injecting the composition according to the present invention into the capsular bag. Furthermore, leakage of EDTA or salts thereof from capsular opening can be effectively prevented by an application of EDTA or salts thereof with viscoelastic material.

This invention offers a medical preparations which is effective in easy and complete debridement of retained lens materials such as lens epithelial cells by an aspiration during a cataract surgery.

50 EXAMPLES

Examples of preparations applying sodium hyaluronate and disodium ethylenediaminetetraacetate will be shown in the following.

55 PREPARATIONS EXAMPLES

Formula 1 :

Sodium hyaluronate

5 (molecular weight 1.8 to 2.2 million) 1.5g

Disodium ethylenediaminetetraacetate 0.336g

10 Sodium chloride 0.9g

Distilled water for injection q.s.

15 Total 100ml

16 Process of preparation :

20 Disodium ethylenediaminetetraacetate and optionally sodium chloride were dissolved in distilled water for injection, and then to the solution was added sodium hyaluronate to make the preparations. Preparations of Formulas 2 to 9 were also made in the same manner.

25

30

35

40

45

50

55

Formula 2 :

Sodium hyaluronate

5 (molecular weight 1.8 to 2.2 million) 1.0g

Disodium ethylenediaminetetraacetate 0.168g

10 Sodium chloride 0.9 g

Distilled water for injection q.s.

Total 100ml

Formula 3 :

Sodium hyaluronate

20 (molecular weight 1.8 to 2.2 million) 2.0g

Disodium ethylenediaminetetraacetate 1.68g

25 Sodium chloride 0.9g

Distilled water for injection q.s.

Total 100ml

Formula 4 :

Sodium hyaluronate

35 (molecular weight 1.9 to 3.9 million) 0.5g

Disodium ethylenediaminetetraacetate 0.336g

40 Distilled water for injection q.s.

Total 100ml

45

50

55

Formula 5 :

Sodium hyaluronate

(molecular weight 1.9 to 3.9 million) 1.5g

Disodium ethylenediaminetetraacetate 0.336g

Distilled water for injection q.s.

Total 100ml

Formula 6 :

Sodium hyaluronate

(molecular weight 0.6 to 1.2 million) 2.5g

Disodium ethylenediaminetetraacetate 0.336g

Sodium hydrogenphosphate 0.05 g

Sodium dihydrogenphosphate q.s.

Distilled water for injection q.s.

Total 100ml

Formula 7 :

Sodium hyaluronate

(molecular weight 0.6 to 1.2 million) 3.0g

Disodium ethylenediaminetetraacetate 0.336g

Distilled water for injection q.s.

Total 100ml

Formula 8 :

Sodium hyaluronate

5 (molecular weight 0.6 to 1.2 million) 2.0g

Disodium ethylenediaminetetraacetate 0.336g

10 Distilled water for injection q.s.

Total 100ml

Formula 9 :

Sodium hyaluronate

20 (molecular weight 0.6 to 1.2 million) 1.5g

Disodium ethylenediaminetetraacetate 0.336g

25 Distilled water for injection q.s.

Total 100ml

Formula 10 :

Sodium hyaluronate

30 (molecular weight 1.8 to 2.2 million) 1.5g

Disodium ethylenediaminetetraacetate 0.336g

35 Isotonic sodium chloride solution q.s.40 Total 100ml

Process of preparation :

45 Disodium ethylenediaminetetraacetate was dissolved in isotonic sodium chloride solution, and then to the solution was added sodium hyaluronate to make the preparations. Preparations of Formulas 11 to 14 were also made in the same manner.

50

55

Formula 11 :

Sodium hyaluronate

5 (molecular weight 1.8 to 2.2 million) 1.5g

Disodium ethylenediaminetetraacetate 0.235g

10 Isotonic sodium chloride solution q.s.

15 Total 100ml

Formula 12 :

Sodium hyaluronate

20 (molecular weight 1.8 to 2.2 million) 1.5g

Disodium ethylenediaminetetraacetate 0.504g

25 Isotonic sodium chloride solution q.s.

30 Total 100ml

Formula 13 :

Sodium hyaluronate

35 (molecular weight 1.8 to 2.2 million) 1.5g

Disodium ethylenediaminetetraacetate 1.009g

30 Isotonic sodium chloride solution q.s.

40 Total 100ml

45

50

55

Formula 14 :

Sodium hyaluronate

(molecular weight 1.8 to 2.2 million) 1.5g

Disodium ethylenediaminetetraacetate 1.513g

Isotonic sodium chloride solution q.s.

Total 100ml

Formula 15 :

Sodium hyaluronate

(molecular weight 1.8 to 2.2 million) 1.5g

Disodium ethylenediaminetetraacetate 0.672g

BSS q.s.

Total 100ml

Process of preparation :

Disodium ethylenediaminetetraacetate was dissolved in BSS, and then to the solution was added sodium hyaluronate to make the preparations. Preparations of Formula 16 was also made in the same manner.

Formula 16 :

Sodium hyaluronate

(molecular weight 0.8 to 1.8 million) 1.5g

Disodium ethylenediaminetetraacetate

BSS q.s.

Total 100ml

EXPERIMENT

50 Experimental Example 1

We examined the effect of disodium ethylenediaminetetraacetate, dissolved in an aqueous solution of sodium hyaluronate, a typical viscoelastic substance, on human lens epithelial cells.

55 Experimental Method

A piece of anterior lens capsule (diameter : 5 to 6mm), obtained by circular capsulotomy during cataract surgery was preserved in MEM media. The piece was soaked for 2 minutes in isotonic sodium

chloride solution containing disodium ethylenediaminetetraacetate and 1.5% by weight sodium hyaluronate (molecular weight : about 2 million). The piece was picked up by a pincette and washed with 10ml of water by a syringe. The remaining extent of lens epithelial cells was observed by an inverted phase contrast microscope.

5 As a control, a piece soaked in 1.5% by weight sodium hyaluronate dissolved in isotonic sodium chloride solution without disodium ethylenediaminetetraacetate was treated in the same manner as the above procedure.

Result

10 We examined the effect of disodium ethylenediaminetetraacetate in each concentration of 15mM (two samples), 30mM (two samples) or 45mM (one sample). In all case, almost all of lens epithelial cells were stripped and no degeneration on the lens capsule itself was observed by a microscope.

On the other hand, in the control about 60% of lens epithelial cells remained.

15 Experimental Example 2

We examined the remaining extent of lens epithelial cells using rabbit lens instead of human lens capsule as in Example 1.

20 A solution of disodium ethylenediaminetetraacetate and 1.5% sodium hyaluronate in isotonic sodium chloride solution was injected into a lens capsule after an extraction of cataractous lens through a small anterior capsulotomy by endocapsular phacoemulsification procedure. After 2 minutes, lens endocapsular epithelial cells attached to the anterior capsule were aspirated off. Result

25 We examined the effect of disodium ethylenediaminetetraacetate in each concentration of 5mM, 7mM or 10mM. In case of 10mM, almost all of epithelial cells were stripped. In case of 5mM and 7mM, small amount of epithelial cells remained. However, such remaining epithelial cells could be completely removed by weak aspiration.

30 Experimental Example 3

35 A solution of disodium ethylenediaminetetraacetate (concentration : 10mM) and 1.5% sodium hyaluronate in isotonic sodium chloride solution was injected into a lens capsule by the same manner as in Example 2. After 2 minutes, aqueous humor was sucked by a syringe and the amount of disodium ethylenediaminetetraacetate leaked into aqueous humor was measured.

35 As a control, disodium ethylenediaminetetraacetate (concentration ; 10mM) dissolved in isotonic sodium chloride solution was used in the same manner as above mentioned procedure.

Result

40 The leakage rates (%) = [(the amount of disodium ethylenediaminetetraacetate leaked into aqueous humor) + (the amount of injected disodium ethylenediaminetetraacetate) X 100] are shown in the following table.

45

50

55

Table

	Leakage Rate (%)
5	
10	Control 19.5 (average of two samples)
15	Preparations of Formula 10 1.1 (average of three samples)

As shown in the table, the leakage rate of the disodium ethylenediaminetetraacetate using sodium hyaluronate was nearly 0 in comparison with the fact that about 20% of the injected disodium ethylenediaminetetraacetate of the control was leaked, whereby the influences of the former on the peripheral intraocular tissues were negligible.

20 A composition for debridement of retained lens materials is disclosed. The composition comprises a viscoelastic material and ethylenediaminetetraacetic acid or salts thereof dissolved in a physiologically acceptable solution.

25 Preferably the viscoelastic material is sodium hyaluronate.

Claims

1. A composition for debridement of retained lens materials comprising a viscoelastic material and ethylenediaminetetraacetic acid or salts thereof both dissolved in a physiologically acceptable solution.
2. A composition as defined in claim 1, wherein the viscoelastic material is sodium hyaluronate.
3. A composition as defined in claim 2, wherein the viscosity of the solution containing the viscoelastic material and ethylenediaminetetraacetic acid or salts thereof is in the range of 10,000 to 100,000 cP.
4. A composition as defined in claim 2, wherein the molecular weight of the sodium hyaluronate is in the range of 600,000 to 4,000,000.
5. A composition as defined in claim 2, wherein the concentration of the ethylenediaminetetraacetic acid or salts thereof is in the range of 5 to 50 millimol/l.
6. A composition as defined in claim 2, wherein ethylenediaminetetraacetic acid salt is disodium ethylenediaminetetraacetate.
7. A composition for debridement of retained lens materials comprising a viscoelastic material and ethylenediaminetetraacetic acid or salts thereof both dissolved in a physiologically acceptable solution, the viscosity of the solution containing the viscoelastic material and ethylenediaminetetraacetic acid or salts thereof being 10,000 to 100,000 cP, and the concentration of the ethylenediaminetetraacetic acid or salts thereof being in the range of 5 to 50 millimol/l.
8. A composition for debridement of retained lens materials comprising sodium hyaluronate having a molecular weight of 600,000 to 4,000,000, and ethylenediaminetetraacetic acid or salts thereof both dissolved in a physiologically acceptable solution, the viscosity of the solution containing the viscoelastic material and ethylenediaminetetraacetic acid or salts thereof being 10,000 to 100,000 cP, and the concentration of the ethylenediaminetetraacetic acid or salts thereof being in the range of 5 to 50 millimol/l.

9. A method for debridement of retained lens materials remaining after a lens extraction from a cataract patient with phacoemulsification-aspiration procedure characterized in that the composition as defined in any one of claims 1 to 8 is injected in the lens capsule and thereafter the retained lens materials are extracted from the capsule.

5

10

15

20

25

30

35

40

45

50

55



Europäisches Patentamt
European Patent Office
Office européen des brevets



⑪ Publication number:

0 464 727 A3

⑫

EUROPEAN PATENT APPLICATION

⑬ Application number: 91110799.3

⑮ Int. Cl.⁵: A61K 9/06

⑭ Date of filing: 28.06.91

⑯ Priority: 29.06.90 JP 172914/90

⑰ Date of publication of application:
08.01.92 Bulletin 92/02

⑱ Designated Contracting States:
BE CH DE DK FR GB IT LI LU NL SE

⑲ Date of deferred publication of the search report:
30.09.92 Bulletin 92/40

⑳ Applicant: SANTEN PHARMACEUTICAL CO., LTD.
9-19, Shimoshinjo 3-chome
Higashiyodogawa-ku Osaka-shi Osaka
533(JP)

㉑ Inventor: Nishi, Okihiro
6-23-10, Hoshida
Katano-shi, Osaka(JP)
Inventor: Nishi, Kayo
6-23-10, Hoshida
Katano-shi, Osaka(JP)

㉒ Representative: BÜHLING, Gerhard, Dipl.-Chem.
Patentanwaltsbüro Tiedtke-BÜHLING-KINNE
Grupe-Pellmann-Grams Bavariaring 4
W-8000 München 2(DE)

㉓ Composition for debridement of retained lens materials.

㉔ A composition for debridement of retained lens materials is disclosed. The composition comprises a viscoelastic material and ethylenediaminetetraacetic acid or salts thereof dissolved in a physiologically acceptable solution.

Preferably the viscoelastic material is sodium hyaluronate.

EP 0 464 727 A3



European Patent
Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 11 0799

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int. Cl.5)	
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	A61K9/06	
X	PATENT ABSTRACTS OF JAPAN vol. 14, no. 294 (C-732)(4237) 26 June 1990 & JP-A-2 096 515 (SANTEN PHARMACEUT CO LTD) 9 April 1990 * abstract * ----	1-2,5-6	A61K9/06	
Y,D	BRITISH JOURNAL OF OPHTHALMOLOGY vol. 72, no. 6, June 1988, LONDON, GB pages 406 - 408; R. C. HUMPHRY ET AL.: 'The Human Anterior Lens Capsule-an attempted chemical debridement of epithelial cells by ethylenediaminetetraacetic acid (EDTA) and trypsin' * the whole document * ----	1-2,4,6, 9	A61K	
Y	US-A-4 328 803 (L. G. PAPE) * claims 1-21 * ----	1-2,4,6, 9	A61K	
A	EP-A-0 244 178 (IOLAB INC.) * column 3, line 12 - line 41; claims 1-9 * ----	1-9	A61K	
A	EP-A-0 258 865 (VISION PHARMACEUTICALS INC) * claims 1-15 * ----	1-9	A61K	
A	US-A-4 486 416 (D. S. SOLL ET AL.) * claims 1-12 * -----	1-9	A61K	
The present search report has been drawn up for all claims				
Place of search	Date of completion of the search	Examiner	SIATOU E.	
BERLIN	24 JULY 1992			
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document		
X : particularly relevant if taken alone				
Y : particularly relevant if combined with another document of the same category				
A : technological background				
C : non-written disclosure				
P : intermediate document				